Overview A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis Status: Recruiting Trial end date: 2024-03-01 Target enrollment: Participant gender: Summary This is a randomized, double-Blind, placebo-controlled Phase 2 Study of Orelabrutinib in Patients with Relapsing-Remitting Multiple Sclerosis. Phase: Phase 2 Details Lead Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.